.png)
Health technology assessment (HTA) has an increasingly important role in healthcare decision-making in China. HTA has been applied to assist health insurance reimbursement decisions on innovative medicines in China. Medicines are evaluated for clinical benefit, cost-effectiveness, and budget impact analyses, and their price is negotiated in light of evidence and budget constraints. Further development of HTA in China faces potential challenges, and how it can be strengthened.
